New drug combo may unlock transplants for 'Impossible-to-Match' kidney patients
NCT ID NCT04827979
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether two drugs, daratumumab and belatacept, can lower the immune system's sensitivity in kidney transplant candidates who are very hard to match. About 19 highly sensitized patients will receive the treatment to see if it reduces their antibody levels or allows them to receive a kidney from a previously incompatible donor. The goal is to shorten their wait time and increase their chance of getting a transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California at San Francisco Medical Center
San Francisco, California, 94143, United States